Navigation Links
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Date:6/20/2008

ypotension (each 13%), herpes zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). Twenty percent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

About Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Between 2001 - 2005, the median age of diagnosis was 70 years. On January 1, 2005 in the U.S., there were approximately 56,200 individuals living with multiple myeloma.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, The Takeda Oncology Company, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, The Takeda Oncology Company, is a leading biopharmaceutical company based in Cambridge, Mass. that markets VELCADE, a cancer product, and has a robust clinical development pipeline of product candidates. The research, development and commercialization activities at Millennium are focused in oncology. By applying its knowledge of the human genome, underst
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Japan Approves CyberKnife System for Extracranial Use
2. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
3. FDA Approves Cymbalta(R) for the Management of Fibromyalgia
4. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
5. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
6. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. FDA Approves Health Claim for Brown Rice
9. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
10. FDA approves HeartMate II mechanical heart pump for heart-failure patients
11. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... August 31, 2014 LabDoor.com tests the ... and supplements. According to their website, “We buy products ... through retail stores and online sites. No manufacturer-supplied samples ... to “Stay Healthy with LabDoor,” a recent study was ... supplements in the United States for Vitamin D3 ...
(Date:8/31/2014)... August 31, 2014 Asked to ... difference between "Bioavailability" and "absorption," Dr. Priya Khan, ... with great interest. "Bioavailability" and "absorption" are ... in the supplement industry, second perhaps only to ... Bioavailability and absorption, while related, are not the ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 Tickets for Brazil ... available at Ticket Down. This is great news for diehard ... the World Cup. To the delight of soccer fans in ... the MetLife Stadium on Tuesday, September 9th. , MetLife ... and New York Jets of the National Football League. The venue ...
(Date:8/31/2014)... NutriGold announces that its whole-food ... and berries, has been approved by ConsumerLab ... purity and label claims. , Most commercially ... genetically modified and chemically produced corn glucose through ... the use of a genetically modified microbe species ...
(Date:8/31/2014)... 2014 Recently, iFitDress.com, a well-known wedding dress ... gorgeous bridesmaid dresses for 2014. What’s more, the firm ... beautiful outfits; all people can enjoy a low rate (up ... valid from this afternoon until September 12. , “We ... outfits for customers from home and abroad. The main purpose ...
Breaking Medicine News(10 mins):Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 2Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 3Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 4Health News:Brazil vs. Ecuador Tickets MetLife Stadium: Ticket Down Slashes Ticket Prices on Ecuador vs. Brazil Tickets in East Rutherford, NJ at the MetLife Stadium 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3Health News:Gorgeous Bridesmaid Dresses For 2014 Now Offered By iFitDress.com 2
... ordered to pay restitution of $2.3 billion and forfeit ... Financial Enterprises (NCFE) executives were sentenced today for their ... financial health of NCFE, Acting Assistant Attorney General Rita ... the Southern District of Ohio announced. NCFE, formerly based ...
... Economic Impact of Biopharmaceutical and Related Sectors to Be Released in ... Dover on Tuesday, March 31 DOVER, ... by We Work for Health - Delaware: WHAT : ... unique new statewide coalition of Delaware,s top leaders in business, ...
... at Princeton ( http://www.princetonhcs.org ) ... -- emergency, inpatient and neonatal intensive care -- through ... (CHOP).(Photo: http://www.newscom.com/cgi-bin/prnh/20090327/NY90350 )CHOP, ... in the world, is ranked first overall in the ...
... to be met by 2012CINCINNATI, March 27, 2009 ... PG ) today announced significantly increased targets ... reflect the company,s continued commitment and progress in ... operations and bettering lives of children in need ...
... 27 The Kroger Co. (NYSE: KR ... Pistachios sold in its family of retail stores because ... the following names in the 31 states where Kroger ... Fred Meyer, Fry,s, King Soopers, Smith,s, Dillons, QFC, City ...
... buildup, experts explain, , , FRIDAY, March 27 (HealthDay News) ... after breast cancer treatment, a new report shows. , ... who have their lymph nodes removed or radiated as ... National Cancer Institute. The swelling condition -- which can ...
Cached Medicine News:Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 3Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 4Health News:Business, Labor, Academia and Bioscience Groups to Launch New Coalition to Promote Medical Innovation and Spark Economic Growth 2Health News:Business, Labor, Academia and Bioscience Groups to Launch New Coalition to Promote Medical Innovation and Spark Economic Growth 3Health News:Business, Labor, Academia and Bioscience Groups to Launch New Coalition to Promote Medical Innovation and Spark Economic Growth 4Health News:University Medical Center at Princeton to Enhance Pediatric Care Through Agreement with The Children's Hospital of Philadelphia 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 3Health News:Kroger Recalls Shelled Pistachios Due to Possible Health Risk 2Health News:Microsurgery May Cut Swelling After Breast Cancer Treatment 2
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Mylan Inc. (Nasdaq: MYL ) today announced ... the company has declared its quarterly dividend of $16.25 per ... a liquidation preference of $1,000.00 per share) payable on Nov. ... of Nov. 1, 2010.  Nov. 15, is also the date ...
... Reportlinker.com announces that a new market research report ... Renal Cell Carcimona Cancer Drug Futures ... EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET ... Carcinoma Cancer Drug Futures includes formats to meet ...
Cached Medicine Technology:Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 2Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 3Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 4Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 5Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 6Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 7Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 8Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 9
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... coaxially on the loupe bar and is ... 4 hours continuous use. The K-L.E.D. comes ... unit that can hold and charge both ... convenient container to keep loupes when not ...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Inquire...
Medicine Products: